Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | Neoadjuvant chemoimmunotherapy: KEYNOTE-522, I-SPY & more

Marleen Kok, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, outlines neoadjuvant chemoimmunotherapy for early triple-negative breast cancer. Specifically discussed is the KEYNOTE-522 trial (NCT03036488), the I-SPY trial (NCT01042379). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).